Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Pulmonary hypertension patients improve from combination therapy

04.12.2006
For patients with pulmonary arterial hypertension (PAH), adding inhaled iloprost to treatment with bosentan—two different classes of drugs often used individually to treat PAH—increases exercise capability, reduces clinical deterioration and, in some cases, improves diagnostic functional class by one stage.

The results of this randomized, multi-center study appear in the first issue for December 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

PAH is a debilitating and potentially fatal disease characterized by the progressive narrowing of blood vessels in the lungs. In 2000, there were 163,000 hospital discharges in which one diagnosis was PAH. Although it is more common in women, ages 21 to 40, it can affect men or women at any age.

Vallerie V. McLaughlin, M.D., of the University of Michigan Medical Center, and nine associates studied 65 PAH patients who were being treated with bosentan, an endothelin receptor antagonist that helps to increase blood flow in the lungs.

The researchers gave 32 patients both bosentan and inhaled iloprost, a prostacyclin analog. The remaining patients received bosentan and a placebo.

Every patient who received the combined therapy increased their six-minute walk distance by more than 98 feet. In addition, 11 climbed from functional class III to class II on the New York Heart Association PAH classification list, which measures how severely patients are limited by their disease. None of the patients in the combined treatment group experienced clinical deterioration by the end of the 12-week study.

Bosentan is often used for initial therapy due to its ease of administration. However, for patients who remain impaired on single drug treatment, Dr. McLaughlin calls the addition of inhaled iloprost is a “potentially attractive clinical option.”

“During the 12-week study, time to clinical worsening was significantly longer in iloprost-treated patients than in placbo patients,” she continued. “None of the iloprost patients met the predefined criteria for clinical worsening, compared with five of the 33 placebo patients.”

The investigators found the drug combination to be both safe and effective. They noted that syncope, a brief loss of consciousness due to a temporary insufficient flow of blood to the brain, was infrequent with the combination therapy, which may be an effect of bosentan.

Since inhaled iloprost therapy requires administration approximately six times per day, the researchers acknowledged that some patients could find this regimen inconvenient and expensive, given the additional cost of combining drugs.

PAH has no known cause and is difficult to diagnose. Symptoms include shortness of breath following exercise, excessive fatigue, dizziness, fainting, and weakness, with symptoms tending to worsen over time.

Suzy Martin | EurekAlert!
Further information:
http://www.thoracic.org

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>